EAACI Congress Kicks Off in Valencia, Spain koreabizwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from koreabizwire.com Daily Mail and Mail on Sunday newspapers.
Jasper Therapeutics, Inc. announced presentations of data from its preclinical and healthy volunteers studies of briquilimab, as well as trial-in-progress presentations from its BEACON and SPOTLIGHT.
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
Phase III data from Novartis confirm the durable efficacy and long-term safety of oral remibrutinib in the treatment of chronic spontaneous urticaria .In the pivotal Phase III REMIX-1 and REMIX-2.